Immodin in the treatment of immunoparalysis in intensive care patients

Czech version

Authors: V. Šrámek ¹; L. Dadák ¹; M. Štouračová ²; P. Štětka ¹; L. Komolíková ³; P. Kuklínek ²
Authors‘ workplace: Anesteziologicko-resuscitační klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta doc. MUDr. Vladimír Šrámek, Ph. D. ¹; Ústav imunologie a alergologie Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Jiří Litzman, CSc. ²; Institut biostatistiky a analýz Lékařské a přírodovědecké fakulty MU Brno, přednosta doc. RNDr. Ladislav Dušek, Ph. D. ³
Published in: Vnitř Lék 2007; 53(9): 954-959
Category: Original Contributions

Overview

Objective:
The objective of the study was to evaluate the effect of administration of the immunoregulating preparation Immodin (Sevapharma, CZ) to influence immunoparalysis in intensive care unit patients.

Method:
A double blind, randomised clinical study was designed for the above purpose. The patients in whom immunoparalysis was detected during monitoring (CD14+ HLA-DR+ ≤ 40 %) were randomised for the administration of Immodin (IM) or placebo (PL); the treatment lasted for 5 days. 45 (25 % of all monitored) patients –⁠ the men/women ratio being 29/16, 60 (54; 65) years of age –⁠ were enrolled in the study (of which 25 IM and 20 PL).

Results:
The patients did not show differences in ICU mortality –⁠ 23 IM patients survived, 2 IM patients died; 15 PL patients survived and 5 PL patients died (p = 0.214). The time of ICU hospitalisation did not differ, either -⁠ 11.6 days for IM patients (8.2; 14.9), 12.6 days for PL patients (9.1; 16.1) (P = 0.659) –⁠ nor did the number of nosocomial infections -⁠ 4 out of 25 IM patients and 4 out of 20 PL patients (p = 0.776). No difference was observed between the patient groups during a 5 day intervention period in terms of SOFA score development (p = 0.954), SIRS days (p = 0.614), sepsis or severe sepsis (respectively p = 0.451 and p = 0.250). No difference was recorded in the trends of basic immunologic parameters, either (CD14+ HLA-DR+ –⁠ p = 0.460, production of TNFα -⁠ p = 0.802, IL-6 –⁠ p = 0.335 , IL-10 –⁠ p = 0.226). The trend of inflammation parameters was also identical (CRP -⁠ p = 0.673, PCT –⁠ p = 0.711).

Conclusion:
The effect of 5 day administration of Immodin to ICU patients with symptoms of immunoparalysis does not differ from that of placebo.

Key words:
intensive care –⁠ immunoparalysis –⁠ immunostimulation –⁠ Immodin –⁠ MODS –⁠ SOFA –⁠ sepsis –⁠ prognosis

Sources

1. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24 : 1125-1128.

2. Kox WJ, Volk T, Kox SN et al. Immunomodulatory therapies in sepsis. Intensive Care Med 2000; 26(Suppl 1): S124-S128.

3. Van den Berk JM, Oldenburger RH, van den Berg AP et al. Low HLA-DR expression on monocytes as a prognostic marker for bacterial sepsis after liver transplantation. Transplantation 1997; 27 : 1846-1848.

4. Hartemink KJ, Paul MA, Spijkstra JJ et al. Immunoparalysis as a cause for invasive aspergillosis? Intensive Care Med 2003; May 24 (Epub; v tisku).

5. Muller Kobold AC, Tulleken JE et al. Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med 2000; 26 : 883-892.

6. Heinzelmann M, Mercer-Jones M, Cheadle WG et al CD14 expression in injured patients correlates with outcome. Ann Surg 1996; 224 : 91-96.

7. Richter A, Nebe T, Kattermann R et al. Immune paralysis in acute pancreatitis -⁠ HLA-DR antigen expression on CD14+ DR+ monocytes. Langenbecks Arch Chir 1996; 381 : 38-41.

8. Payen D, Faivre V, Lukascewicz AC et al. Assesment of immunological status in the critically ill. Minerva Anesthesiol 2000; 66 : 351-357.

9. Nierhaus A, Schneider CG, Frings D et al. Sequential assessment of immune function in SIRS and sepsis:monocyte function, severity and outcome. Intensive Care Med 2001; 27(Suppl 2): S199.

10. Monneret G, Lepape A, Voirin N et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006; 32 : 1175-1183.

11. Monneret G, Finck ME, Venet F et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 2004; 95 : 193-198.

12. Ploder M, Pelinka L, Schmuckenschlager C et al. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 2006; 25 : 129-134.

13. Patel RT, Deen KI, Youngs D et al. Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 1994; 81 : 1306-1308.

14. Geppert A, Dorninger A, Delle-Karth G et al. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2006; 34 : 2035-2042.

15. Taniguchi T, Koido Y, Aiboshi J et al. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999; 27 : 1262-1264.

16. Kox WJ, Bone RC, Krausch D et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 1997; 157 : 389-393.

17. Nierhaus A, Montag B, Timmler N et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 2003; 29 : 646-651.

18. Weiss M, Voglic S, Harms-Schirra B et al. Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission. Intensive Care Med 2003; 29 : 904-914.

19. Stephens DP, Fisher DA, Currie BJ. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J 2002; 32 : 143-148.

20. Vrubel J, Hána I. Léčení buněčné imunodeficience u chirurgických nemocných. Cesk Epidemiol Mikrobiol Imunol 1993; 42 : 93.

21. Bosáková H, Řehořková D, Hude P et al. Problematika imunodeficience u polytraumatizovaných pacientů a upacientů s paraněním pateře -⁠ možnosti jejího ovlivnění. In: Zazula R at al. Ročenka intenzivní medicíny 2003. Praha: Galén: 167-168.

22. Průcha M, Limberk B. Syndrom sekundárního posttraumatického imunodeficitu u pacientů anesteziologicko-resuscitačního oddělení. Možnosti imunomodulační terapie. Cesk Epidemiol Mikrobiol Imunol 1993; 42; 116-120.

23. Vincent JL, de Mendonca A, Cantraine F et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 1998; 26 : 1793-1800.

24. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20 : 864-874.

25. Bernard GR, Vincent JL, Laterre PF et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344 : 699-709.

26. Alkharfy KM, Kellum JA, Matzke GR. Unintended immunomodulation: part I. Effects of common clinical conditions on cytokine biosynthesis. Shock 2000; 13 : 333-345.

27. Alkharfy KM, Kellum JA, Matzke GR. Unintended immunomodulation: part II. Effects of pharmacological agents on cytokine activity. Shock 2000; 13 : 346-360.